Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14XMD | ISIN: CA03879J1003 | Ticker-Symbol: I9DN
Tradegate
20.11.24
15:46 Uhr
3,294 Euro
+0,020
+0,61 %
1-Jahres-Chart
ARBUTUS BIOPHARMA CORPORATION Chart 1 Jahr
5-Tage-Chart
ARBUTUS BIOPHARMA CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
3,2703,33415:53
3,2703,33015:53

Aktuelle News zur ARBUTUS BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrBarinthus Biotherapeutics: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B10
ARBUTUS BIOPHARMA Aktie jetzt für 0€ handeln
FrArbutus Biopharma Corporation: Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon11850% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...
► Artikel lesen
FrArbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B194Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom...
► Artikel lesen
FrArbutus Biopharma Corp - 8-K, Current Report2
06.11.Arbutus Fades on Q4 Results18
06.11.Arbutus Biopharma GAAP EPS of -$0.10 misses by $0.01, revenue of $1.34M misses by $0.53M4
06.11.Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update141Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase...
► Artikel lesen
06.11.Arbutus Biopharma Corp - 8-K, Current Report4
23.10.Arbutus Biopharma Corporation: Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update16
15.10.Arbutus Biopharma Corporation: Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 202411
14.10.Arbutus Biopharma gibt Ruhestandskonditionen für Führungskraft bekannt13
14.10.Arbutus Biopharma announces officer retirement terms2
11.10.Arbutus Biopharma Corp - 8-K, Current Report7
01.10.Arbutus Biopharma Corporation: Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference11
03.09.Arbutus Biopharma Corporation: Arbutus to Participate in Two Upcoming Investor Conferences16
08.08.Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans7
01.08.Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts19
01.08.Arbutus cutting 40% of workforce to focus on phase 2 hepatitis b asset imdusiran8
01.08.UniQure, Arbutus and HilleVax all lay off staff as biotechs streamline operations and cut costs4
01.08.XFRA I9DN: WIEDERAUFNAHME/RESUMPTION258FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1